1. Fang, Douglas D, Zhang, Bin, Gu, Qingyang, Mao, Mao, Chan, Chi-Chung. . HIP1-ALK, a novel ALK fusion variant that responds to crizotinib. In Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 9, 285-94. doi:10.1097/JTO.0000000000000087. https://pubmed.ncbi.nlm.nih.gov/24496003/
2. Prasad, Peeyush, Chongtham, Jonita, Tripathi, Satyendra Chandra, Mittal, Shivani Arora, Srivastava, Tapasya. 2024. Targeted inhibition of NRF2 reduces the invasive and metastatic ability of HIP1 depleted lung cancer cells. In Biochemical and biophysical research communications, 733, 150676. doi:10.1016/j.bbrc.2024.150676. https://pubmed.ncbi.nlm.nih.gov/39303527/
3. Bettencourt, Conceição, Miki, Yasuo, Piras, Ignazio S, Huentelman, Matt J, Holton, Janice L. 2021. MOBP and HIP1 in multiple system atrophy: New α-synuclein partners in glial cytoplasmic inclusions implicated in the disease pathogenesis. In Neuropathology and applied neurobiology, 47, 640-652. doi:10.1111/nan.12688. https://pubmed.ncbi.nlm.nih.gov/33368549/